Skip to content
Menu

Oppenheimer Initiates Coverage On Pelthos Therapeutics with Outperform Rating, Announces Price Target of $50

Benzinga Newsdesk 1 year ago

NewsPrice TargetInitiationAnalyst Ratings

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Oppenheimer analyst Jeff Jones initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Outperform rating and announces Price Target of $50.

Oppenheimer analyst Jeff Jones initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Outperform rating and announces Price Target of $50.

Read at benzinga.com